- Amgen shares new Tavneos analysis in effort to resolve FDA disputeAmgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market. The submission, made Thursday, includes an independent r…Endpoints · 3h ago↗ source
- Ipsen’s Bylvay fails key trial in children with rare liver diseaseIpsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies. Babies with the disease can get a Kasai proc…Endpoints · 6h ago↗ source
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrappedSanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.